We thank all people who accepted to participate in this study We

We thank all people who accepted to participate in this study. We thank the technicians from the Center for Hemotherapy and Hematology of Pará Foundation — HEMOPA. This study was supported by Universidade Federal do Pará (UFPA) (PPQ-CCB-0232/2010). “
“Anemia is common in older

adults, with a prevalence of approximately 10% in community-dwelling men and women aged 65 and older, rising to 20–35% in those aged 85 and above [1] and [2]. Although on an individual basis anemia in older adults is frequently overlooked or ignored, studies Bcl2 inhibitor from numerous older populations throughout the developed world have consistently demonstrated an association between anemia, which is typically mild, and poor clinical outcomes, including decreased physical performance and strength [3] and [4], decreased mobility function [5], impairment in instrumental activities of daily living [6], increased frailty [7], impaired quality of life [8], decreased cognitive function [9], and increased mortality [10] and [11]. Anemia has many causes. Data from large population-based surveys have ascertained several broad etiologies of anemia in older adults: iron deficiency that is possibly nutritional but more often secondary see more Ergoloid to blood

loss, anemia associated with inflammation, anemia due to renal insufficiency, anemia due to nutritional deficiencies, and unexplained anemia of the elderly (UAE). UAE, a relatively new diagnostic category, is consistently

found in approximately 30–44% of older anemic subjects [1], [2] and [12]. Prospective studies incorporating a thorough clinical evaluation have demonstrated similar proportions of UAE [13] and [14]. Iron deficiency in older adults may be difficult to identify, with the diagnosis confirmed only by response to a trial of iron supplementation [13]. In addition, patients who do not respond to oral iron may have a rise in hemoglobin following the administration of intravenous iron [15]. The Partnership for Anemia: Clinical and Translational Trials in the Elderly (PACTTE) consortium was formed to investigate treatment strategies in subjects with UAE. This study was designed as the first PACTTE interventional study, utilizing intravenous iron sucrose (IVIS) in a subset of subjects with UAE. The study was designed as a randomized, wait list control trial. Subjects were randomized to receive IVIS either immediately after enrollment (immediate intervention group) or after an initial waiting period of 12 weeks (wait list control group).

Comments are closed.